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Abstract
Recurrence of Cushing’s disease after successful transsphenoidal surgery occurs in 
some 30% of the patients and the response to desmopressin shortly after surgery has 
been proposed as a marker for disease recurrence. The aim of the present study was to 
evaluate the response to desmopressin over time after surgery. We tested 56 patients 
with Cushing’s disease in remission after transsphenoidal surgery with desmopressin for 
up to 20 years after surgery. The ACTH and cortisol response to desmopressin over time 
was evaluated in patients on long-term remission or undergoing relapse; an increase by 
at least 27 pg/mL in ACTH levels identified responders. The vast majority of patients who 
underwent successful adenomectomy failed to respond to desmopressin after surgery 
and this response pattern was maintained over time in patients on long-term remission. 
Conversely, a response to desmopressin reappeared in patients who subsequently 
developed a recurrence of Cushing’s disease, even years prior to frank hypercortisolism. 
It appears therefore that a change in the response pattern to desmopressin proves 
predictive of recurrence of Cushing’s disease and may indicate which patients require 
close monitoring.
Introduction
First-line treatment of Cushing’s disease is surgical 
removal of the ACTH-secreting pituitary tumor and 
worldwide remission rates range from 60 to 80% (1, 2, 
3). The tumor may recur, however, most often within 
two years of surgery but sometimes even decades after 
cure. Estimates of recurrence vary from 5 to 30% (4, 5, 
6) indicating that up to one-fifth of the patients may 
experience a relapse of hypercortisolism. From a clinical 
viewpoint, this translates into the need for long-term 
surveillance of patients in remission and repeated testing 
with a variety of hormonal challenges. Indeed, as with 
the diagnosis of Cushing’s disease, the establishment of 
recurrence may be straightforward in some patients and 
challenging in others. This has given rise to the search for 
reliable markers of recurrence (1, 7), usually at immediate 
postsurgical testing, but none has proven fully predictive 
for long-term, relapse-free survival.
One potential recurrence prognostic is desmopressin 
testing, a procedure also used during the diagnostic 
work-up of Cushing’s disease. Administration of 
desmopressin, a long-acting vasopressin analog, has in 
fact proven useful to distinguish Cushing’s disease from 
pseudo-Cushing states (8, 9, 10, 11, 12, 13, 14) as it has 
been shown to stimulate ACTH secretion in tumoral 
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corticotropes (15, 16, 17, 18, 19). Along the same line, 
a response to desmopressin after surgery may be taken 
to indicate the persistence of tumoral corticotropes (20, 
21, 22, 23, 24). Postsurgical desmopressin testing has 
been used both to establish remission (20, 21, 24) and 
to predict relapse (22, 23) with testing performed shortly 
after surgery.
The aim of the present study was to assess the pattern 
of ACTH/cortisol responses to desmopressin in the years 
following transsphenoidal surgery in patients with 
Cushing’s disease on long-term remission and to establish 
whether changes in the response to desmopressin in 
patients during follow-up can prove an early marker for 
recurrence.
Subjects and methods
Patients
We evaluated 56 patients with Cushing’s disease 
(43 women, 13 men, mean age 39.4 ± 1.47  years, range 
15–67  years) in remission after transsphenoidal surgery 
and followed for 2–23 years (mean 130.1 ± 8.93 months). 
The diagnosis of Cushing’s disease had been established 
by standard diagnostic criteria (4, 25) and confirmed by 
surgical cure and/or pathology. Outcome of surgery had 
been established on both clinical and laboratory grounds 
with testing performed within 5 days of surgery. Patients 
in remission presented normal urinary-free cortisol (UFC) 
levels and low-normal morning serum cortisol, signs and 
symptoms of adrenal insufficiency and required steroid 
replacement therapy. Replacement therapy was started 
with cortisone acetate 37.5 mg/daily and mean length 
of replacement therapy was 14.7 ± 1.78  months after 
exclusion of 2 patients who could not be weaned off 
steroid replacement and are currently still being treated at 
16 and 17 years after surgery. Patients who subsequently 
developed elevated UFC, abnormal overnight suppression 
test (OST; cortisol >3 µg/dL after 1 mg dexamethasone 
administered at midnight (26)) and clinical signs of 
hypercortisolism were considered relapse. The first 
available abnormal UFC was taken to indicate time-to-
relapse; relapse occurred 87.0 ± 13.58  months (range 
24–162 months) after surgery.
Patients were classified into two groups according 
to the criteria described above: long-term remission 
(43 patients) and relapse (13 patients; Table  1); 
43 patients (33 remission, 10 relapse) had been tested 
with desmopressin also prior to surgery. Postsurgical 
evaluation was performed, usually at yearly intervals, by 
means of clinical evaluation, UFC measurement, OST and 
desmopressin testing.
Approval for the present study was obtained by the 
Ethical Committee of the Istituto Auxologico Italiano and 
informed consent was obtained from all participants prior 
to testing.
Desmopressin testing was performed in the morning 
according to our usual protocol (8, 12). Briefly, 10 µg 
desmopressin (Ferring Pharmaceuticals) was administered 
as an i.v. bolus and blood samples for ACTH and cortisol 
estimation obtained before and 10, 20, 30, 45, 60, 90 and 
120 min after drug administration. Blood pressure and 
heart rate were monitored throughout the procedure. 
Patients were considered responsive if ACTH increased 
by at least 27 pg/mL (6 pmol/L) (8). This cut-off yielded 
the highest diagnostic accuracy to discern patients with 
Cushing’s disease from normal-weight and obese subjects 
as well as from those with pseudo-Cushing. Given that 
desmopressin testing in the current setting is used to 
distinguish recurrence of the corticotrope adenoma vs 
normal HPA physiology, it appears appropriate to use the 
same criterion.
Table 1 Demographic data and early postsurgical evaluation in patients with Cushing’s disease.
 
 
Patients
 
 
Age (years)
 
 
Sex
 
 
Adenoma
 
Urinary free 
cortisol (µg/24 h)
 
8:00 h cortisol 
(µg/dL)
 
 
12:00 h cortisol (µg/dL)
Overnight 
suppression test 
(µg/dL)
All patients 
(n = 56)
39.4 ± 1.47 43 women
13 men
32 micro
4 macro
20.3 ± 1.74 4.73 ± 0.641 1.76 ± 0.234 1.22 ± 0.116
Long-term 
remission 
(n = 43)
39.1 ± 1.59 31 women
12 men
39 micro
4 macro
18.9 ± 1.95 4.72 ± 0.732 1.43 ± 0.228* 1.21 ± 0.136*
Relapse 
(n = 13) 
40.6 ± 3.63 
 
12 women
1 man 
13 micro 
 
24.3 ± 4.34 
 
6.55 ±1.404 
 
3.00 ± 1.104 
 
1.94 ± 0.301 
 
*P < 0.05 vs relapse. To convert into SI, multiply urinary-free cortisol by 2.759, serum cortisol by 27.59.
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Assays
Plasma ACTH was measured by two-site 
immunoradiometric assay (Allegro, Nichols Institute 
Diagnostics, San Juan Capistrano, CA, USA) up to 2010 
and then by chemiluminescent immunoassay (Elecsys, 
Roche). Plasma cortisol and UFC, the latter after urine 
extraction with dichloromethane, were measured by 
RIA (Byk-Sangtec Diagnostica, Dietzenbach, Germany 
and DPC, Los Angeles, CA, USA, respectively) until 2010 
and then by chemiluminescent immunoassay (Elecsys, 
Roche). Stringent quality control procedures within the 
laboratory ensured optimal commutability and linearity 
between assays. Overall, intra- and interassay coefficients 
of variations are 3.2 and 8.2% for ACTH, 3.0 and 4.7% for 
serum cortisol and 3.5 and 6.2% for UFC. Normal ranges 
in our laboratory are 10–50 pg/mL and 9–64 pg/mL for 
ACTH with immunometric and chemiluminescent assays, 
respectively, and 10–80 μg/24 h and 17–136 µg/24 h for 
UFC with immunometric and chemiluminescent assays, 
respectively; normal range for serum cortisol is 5–25 μg/dL 
with either assay.
Statistical analyses
The ACTH and cortisol responses to DDAVP were 
evaluated as absolute peak, absolute increment and 
percentage increment compared to basal values. Student’s 
t-test for paired data was used for comparisons of ACTH 
concentrations in the same patient, whereas non-
parametric tests, i.e., Mann–Whitney and Wilcoxon, 
were used, as appropriate, for the analysis of derived 
variables. Chi-square and Fisher’s exact tests were used for 
comparison of qualitative variables. Logistic regression 
analysis was performed to identify predictor variables; 
Receiver Operator Characteristic (ROC) analysis was 
performed to establish diagnostic efficiency and calculate 
Youden’s J index (27). Data are expressed as mean ± s.e. 
or median and 25th/75th centile range. Statistical 
significance was accepted for P < 0.05. Statistical analyses 
were performed with Statview (SAS Institute, Cary NC, 
USA) and MedCalc (MedCalc Software, Ostend, Belgium).
Results
Early postoperative evaluation
Table  1 shows hormonal data in patients upon early 
postsurgical evaluation. i.e., <1  week after surgery. 
As expected, UFC, and morning and midnight 
serum cortisol as well as cortisol after OST were 
significantly lower compared to presurgical levels in 
all patients (UFC 20.3 ± 1.74 vs 416.1 ± 58.18 μg/24 h, 
respectively, P < 0.0001; morning cortisol 4.73 ± 0.641 
vs 19.9 ± 1.12 μg/dL, P < 0.0001; midnight cortisol 
1.76 ± 0.234 vs 18.6 ± 1.38 μg/dL, P < 0.0001; cortisol after 
OST 1.22 ± 0.116 vs 16.4 ± 1.69 μg/dL, P < 0.0001). No 
significant differences in immediate postoperative UFC 
or morning serum cortisol values were observed between 
patients on long-term remission or relapse; conversely, 
midnight serum cortisol and cortisol after OST levels 
were higher in patients who relapsed (Table  1). No 
differences in length of replacement therapy were 
observed between patients in long-term remission and 
relapse (17.2 ± 2.18 vs 13.6 ± 3.06  months, N.S., after 
exclusion of 2 patients still on replacement therapy, as 
described earlier).
Forty-seven patients underwent the desmopressin test 
immediately after surgery and the ACTH peak increment 
decreased on average from 176.8 ± 32.49 pg/mL before 
surgery to 14.7 ± 3.61 pg/mL after surgery (P < 0.001). 
Comparison of pre- and postsurgical responses revealed 
that the response to desmopressin disappeared in all 
but 6 patients, 4 long-term remissions (last follow-up 
44–94 months) and 2 relapses (Fig. 1). Overall, the ACTH 
response to desmopressin was comparable between 
patients on long-term remission and relapses (incremental 
peak 14.6 ± 4.27 vs 9.4 ± 2.08 pg/mL, N.S., respectively) as 
was the percentage of non-responders (88.9 vs 80%, P = 0.61 
by Fisher’s exact test). Analysis of the ACTH response as 
percentage over baseline also did not differ (209.6 ± 20.51 
vs 197.9 ± 29.68%, N.S., for remission and relapse, 
respectively), nor did the cortisol response (incremental 
peak 2.32 ± 0.66 vs 2.66 ± 0.85 µg/dL, percent increase 
148.7 ± 16.62 vs 175.7 ± 29.66%, N.S., for remission and 
relapse, respectively). In fact, no variable was retained 
at the stepwise entry logistic regression analysis except 
for OST (coefficient −1.253 ± 0.618, P < 0.05). It follows 
that the response to desmopressin observed at early 
postoperative evaluation was not predictive of long-term 
remission in our series.
Long-term evaluation
All patients underwent desmopressin testing during 
postoperative follow-up for up to 275 months; in total, 
309 tests were performed. Patients in long-term remission 
displayed comparable responses over time (Fig.  2, left 
panel) and, indeed, no discernible differences in ACTH peak 
increment were observed at repeated-measures ANOVA 
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(F = 1.46, N.S., Fig. 2, right panel). Of note, in patients in 
long-term remission, no differences were observed between 
tests performed prior to 2010 (immunoradiometric assay, 
n = 194) and after 2010 (chemiluminescent immunoassay; 
n = 44) as regards baseline ACTH concentrations 
(25.7 ± 1.81 vs 23.63 ± 1.79 pg/mL, N.S.), ACTH peak 
(65.8 ± 8.44 vs 47.6 ± 5.37 pg/mL, N.S.) and ACTH peak 
increment (40.1 ± 7.51 vs 23.97 ± 4.28 pg/mL, N.S.). 
Likewise, no differences were observed for cortisol 
concentrations measured before (radioimmunoassay) and 
after 2010 (chemiluminescent immunoassay) at baseline 
(8.8 ± 0.52 vs 8.7 ± 0.36 µg/dL, N.S.), peak (14.1 ± 0.94 vs 
13.2 ± 0.87 µg/dL, N.S.) and incremental peak (5.3 ± 0.55 
vs 4.5 ± 0.69 µg/dL, N.S.).
As regards individual responses, in addition to the 
4 patients tested early after surgery who displayed persistent 
ACTH responses to desmopressin although in remission, 
5 additional patients in long-term remission (follow-up 
75–273 months) presented responses to desmopressin at 
postsurgical evaluations; this pattern did not change over 
Figure 1
ACTH response to desmopressin before surgery 
and at early postsurgical evaluation. Graphs show 
ACTH incremental peak before (filled circles) and 
after (empty circles) surgery in each patient 
tested at both times. Dashed line indicates the 
criterion for response to desmopressin.
Figure 2
ACTH response to desmopressin at long-term follow-up in patients on stable remission. Left panel: ACTH concentrations upon desmopressin 
administration (arrow) over 2 h are depicted. Average values at different time points after surgery are color-coded as shown. Right panel: range of ACTH 
peak increments during follow-up. Bars comprise 25th, 50th and 75th centiles, error bars 10th and 90th centiles and individual outliers are shown. 
Dashed line indicates a positive response.
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the entire observation period. In all other patients, even 
10 years after surgery, the ACTH response to desmopressin 
fell easily within the range of responses recorded in 
normal subjects (median incremental peak 14.9 pg/mL, 
10th centile: 4.8 pg/mL, 90th centile: 27.0 pg/mL 
(8)). Patients who did not respond to desmopressin prior 
to surgery maintained this response pattern throughout 
(follow-up range 2–7 years).
Conversely, the response pattern to desmopressin 
changed over time in patients who relapsed (time-to-
relapse 24–162 months). At early postsurgical evaluation, 
patients had failed to mount a significant response 
to desmopressin and had thus been considered non-
responders (as described earlier, Fig.  3). However, the 
response pattern changed over time and clear-cut 
ACTH increases were registered at different time points 
after surgery (Fig.  3). Once the response pattern had 
changed to responder status, this trend was confirmed at 
subsequent testing; indeed, all patients were responsive to 
desmopressin by the time of relapse (average incremental 
peak 97.1 ± 27.46 pg/mL; Fig.  3). Most interestingly, 
in 9 patients with multiple testing, the response to 
desmopressin had become evident prior to the recurrence 
of hypercortisolism (Fig.  3). In fact, UFC and OST were 
indicative of normal HPA axis function at the time the 
response to desmopressin changed and became clearly 
altered only months to years after this first response 
(Table 2).
As mentioned earlier, the criterion for response to 
desmopressin was chosen on the basis of the response 
observed in normal subjects (8) and, indeed, patients in 
remission retained a pattern consistent with normal HPA 
secretion (as described earlier). We also performed the ROC 
analysis on our chosen criterion, in comparison with the 
percent ACTH increase, as used by other investigators (20). 
Comparison of ROC curves revealed that absolute ACTH 
increase was superior to percent ACTH increase (ROC AUC 
0.836 ± 0.0341 vs 0.713 ± 0.0434, P < 0.001, respectively, 
Supplementary Fig. 1, see section on supplementary data 
given at the end of this article). Indeed, Youden’s index for 
absolute ACTH increase was indicative of good diagnostic 
effectiveness at 0.6855 (95% C.I. 0.563; 0.776), whereas 
the same parameter for percent ACTH increase was far 
lower 0.3926 (95% C.I. 0.243; 0.506).
Figure 3
ACTH response to desmopressin at long-term 
follow-up in patients who relapsed. Incremental 
peak ACTH concentrations are repeated testing 
over time in the 13 patients shown; white circles 
indicate concurrent normal UFC/OST; gray circles 
indicate abnormal UFC/OST. Dashed line indicates 
a positive response.
Table 2 Hormonal responses in patients who experienced recurrrence in whom the response to desmopressin preceded 
full-blown hypercortisolism.
Pt #
Reappearance of response to desmopressin* Relapse
Months after 
surgery
ACTH incremental 
peak ACTH in (pg/mL) UFC (µg/24 h) OST (µg/dL)
Months after 
surgery
ACTH incremental 
peak ACTH in (pg/mL) UFC (µg/24 h) OST (µg/dL)
1 102 57.3 41.0 0.9 147 73 147 4.6
2 16 30.9 35.5 1.2 29 103.6 188 3.5
3 80 46.1 50.7 2 108 48.4 134 5.9
4 66 43.1 28.8 0.9 162 397 1035 9.6
5 34 31.9 23.8 0.7 115 173 693 8.4
6 18 29 46 2.7 44 47.1 267 11
7 59 27.7 60.4 2 85 30.3 180 7.8
8 80 28.4 31.6 0.9 116 84.4 430 3.5
9 25 31.5 13.3 1.0 36 46.1 460 11.7
*Criteria for response: ACTH peak increment >27 pg/mL. UFC: urinary-free cortisol (abnormal > 80 µg/24 h); OST: cortisol after 1 mg dexamethasone 
(abnormal >3 µg/dL (26)).
To convert into SI, multiply urinary-free cortisol by 2.759, serum cortisol by 27.59.
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Discussion
The management of patients with Cushing’s disease 
requires considerable expertise. First, diagnosis 
of endogenous cortisol excess is by no means 
straightforward (25), especially in mild cases (28), and 
then transsphenoidal surgery – the first choice treatment 
– has to prove successful. Furthermore, once the patient 
is in remission, the specter of relapse has to be taken into 
account and patients monitored for years (29). In this 
context, while relapse may sometimes occur rapidly, in 
most cases this appears a rather slow, lengthy process 
and repeated evaluations have to be performed over 
time until full-blown hypercortisolism is unmistakably 
manifest. The physician may therefore have to assess 
pituitary–adrenal function for years, which is costly and 
possibly unnecessary if patients do not relapse. Several 
criteria have been proposed to establish which patients 
are at risk for relapse and warrant close follow-up and 
which are unlikely to present disease recurrence and can 
be monitored more loosely. Morning serum cortisol after 
surgery (30) is one such criterion, although prediction is 
by no means absolute (31) as up to 25% of the patients 
with undetectable/low cortisol relapse at a future date 
(5, 32). Other criteria have also been proposed as predictors 
of relapse, such as findings at pathology (2), response 
to CRH (4, 33), inhibition after 1 mg dexamethasone 
overnight (34, 35), plasma ACTH levels (36) and late-night 
salivary cortisol (37). None however provides absolute 
certainty for relapse-free survival and the search for more 
accurate indicators is on-going.
One recent addition to the panel of predictors is 
the postsurgical response to desmopressin. This test has 
proven useful to distinguish patients with Cushing’s 
disease from patients with pseudo-Cushing (11, 28) and 
there are also several studies reporting its use after surgery. 
Stimulation with desmopressin shortly after surgery may 
help confirm successful removal of tumoral corticotropes, 
as the response to desmopressin is expected to disappear 
in these patients (20, 21, 23). Conversely, if the response 
to desmopressin persists after surgery, then failure is likely 
(20, 21, 23). Overall, some 50–80% of individuals who 
presented a response to desmopressin though in remission 
subsequently relapsed (20, 23); thus, the test appeared 
a possible but not fully reliable predictor. Moreover, 
no specific cut-off could be identified; indeed, criteria 
for response varied from absolute cortisol increase over 
7 µg/dL (23) to percentage ACTH and cortisol increase over 
30% and 20%, respectively (20). Variants of desmopressin 
testing, i.e., dexamethasone-suppressed desmopressin 
stimulation, have also been proposed but again results 
proved promising though not fully predictive of surgical 
outcomes (38, 39).
It appears, therefore, that immediate postsurgical 
evaluation may not be the best timeframe to predict an 
occurrence which may take place years after surgery. 
In fact, it has been suggested that subtle alterations of 
the hypothalamic–pituitary–adrenal axis may develop 
over time and represent an early predictor of relapse 
(40), thus identifying patients who necessitate closer 
monitoring. We decided to review the response pattern to 
desmopressin in a large series of patients with Cushing’s 
disease in remission after pituitary surgery in order to 
identify whether the response to desmopressin may 
represent an early marker of relapse and, indeed, can state 
that this is the case.
On the one hand, analysis of response patterns in 
patients in stable, long-term remission showed that the 
response to desmopressin is modest and that this response 
pattern is maintained for years, even decades. The small 
increase in ACTH upon desmopressin stimulation, indeed, 
is reminiscent of the response observed in normal subjects 
(8), supporting the concept that normal hypothalamic–
pituitary–adrenal axis physiology is restored in patients 
on long-term remission (41).
Conversely, patients who relapsed changed their 
response pattern over time. In fact, although ACTH failed 
to increase at immediate postsurgical evaluation in these 
patients – in keeping with remission status – ACTH peak 
levels increased at subsequent testing. This represented a 
clear deviation from the previous, bland response pattern, 
suggesting a reprise of the ACTH secretory response typical 
to Cushing’s disease. Indeed, as both normal individuals 
and patients in remission from Cushing’s disease do 
not mount a significant ACTH secretory response after 
desmopressin stimulation, a deviance from this pattern is 
highly informative.
Several mechanisms have been postulated to underlie 
this peculiar secretory response. Desmopressin has a 
strong affinity for the vasopressin V2 and V3 receptor 
subtypes (42, 43) and available evidence points to an 
involvement of both receptors in the stimulatory effect of 
desmopressin on ACTH secretion by tumoral corticotropes 
(16, 17, 44). On the other hand, mechanisms other than 
direct desmopressin action at the pituitary level have 
been postulated given that some patients fail to respond 
to desmopressin in vitro notwithstanding a clear in vivo 
response (16). In these patients, relapse would imply 
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re-enacting the deregulation in suprapituitary control 
mechanisms which enables the response to desmopressin, 
reminiscent of the hypothalamo-derived hypothesis for 
corticotrope tumor pathogenesis (45, 46).
In the present study, we applied the criterion 
developed to diagnose patients with Cushing’s disease 
prior to surgery (8) to identify a response to desmopressin 
after surgery. This strategy is in line with other studies 
(20, 38) and proved rational as patients in long-term 
remission presented a modest – if any – increase in ACTH 
upon desmopressin stimulation, well within the range 
observed in normal subjects. Indeed, ROC curve analysis 
and Youden’s index confirmed its good diagnostic 
effectiveness and superiority to percent ACTH increase.
Of note, reappearance of the ACTH response to 
desmopressin occurred months to years prior to full-
blown recurrence of hypercortisolism; indeed, the 
interval between the appearance of a response to 
desmopressin and detection of increased UFC levels 
or absent OST suppression ranged from 1 to 8  years in 
patients tested at regular intervals. A similar pattern had 
been observed in 2 patients reported by Dall’Asta (47) and 
in some patients submitted to dexamethasone-suppressed 
desmopressin testing (48). Reappearance of the response 
to vasopressin analogs and/or to CRH prior to overt 
recurrence had also been reported in some patients from 
a French series (40). This suggests that corticotrope tumor 
cell re-growth is associated with deregulation of the 
response to desmopressin quite some time before giving 
rise to excess cortisol secretion. It follows that repeat 
desmopressin testing in patients in remission is useful 
to identify patients who mandate closer monitoring and 
those who can be followed more loosely. A shift toward 
desmopressin responsiveness in patients who previously 
failed to respond is likely to be followed by recurrence of 
hypercortisolism and should prompt careful surveillance 
allowing timely detection of relapse. Conversely, constant, 
absent responses to desmopressin may allow a less strict 
monitoring schedule. Interestingly, changes in late-night 
salivary cortisol have also been reported to herald full-
blown recurrence of hypercortisolism although there is 
considerable variability in salivary cortisol sequential 
measures (49, 50). One study reported that responses to 
vasopressin analogs preceded changes in midnight salivary 
cortisol in 8 out of 14 patients (40); thus, there might 
indeed be a specific advantage to desmopressin testing 
as an early predictor of disease recurrence. Definition of 
threshold markers and timing of testing for desmopressin 
as well as other predictive parameters will require further 
large-scale, and possibly collaborative, studies.
In conclusion, our study has shown that patients 
with Cushing’s disease on long-term surgical remission 
maintain their response pattern to desmopressin over 
time. Conversely, a change in the response pattern 
over time anticipates a recurrence of Cushing’s disease. 
Reappearance of the response to desmopressin represents 
an alert for closer monitoring.
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